New cell therapy trial targets devastating amyloid disease
NCT ID NCT07081646
Summary
This study is testing a new cell therapy called AZD0120 for people with AL amyloidosis that has come back or hasn't responded to prior treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target the disease, and then infuse them back. The main goals are to see if the treatment is safe and if it can help patients achieve a deep response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGPhoenix, Arizona, 85028, United States
-
Research Site
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
-
Research Site
RECRUITINGTampa, Florida, 33612, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGDetroit, Michigan, 48201, United States
-
Research Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Research Site
RECRUITINGSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGNew York, New York, 10032, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44195, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37232, United States
-
Research Site
WITHDRAWNCalgary, Alberta, T2N 5G2, Canada
-
Research Site
NOT_YET_RECRUITINGCalgary, Alberta, T2N 5G2, Canada
-
Research Site
WITHDRAWNToronto, Ontario, M5G 2M9, Canada
-
Research Site
NOT_YET_RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Research Site
WITHDRAWNLondon, NW3 2PF, United Kingdom
-
Research Site
NOT_YET_RECRUITINGLondon, NW3 2PF, United Kingdom
Conditions
Explore the condition pages connected to this study.